Related Experiment Video
Updated: Aug 19, 2026
Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
Published on: April 4, 2019
RotaTeq (sanofi pasteur/Wistar Institute/Children's Hospital of Philadelphia)
1UMR 2472 Virologie Moléculaire et Structurale, CNRS, 1 Avenue de la Terrasse, 91198 Gif-sur-Yvette, France. ulrich.desselberger@vms.cnrs-gif.fr
Abstract:
Sanofi pasteur MSD (a joint venture between Merck & Co and sanofi pasteur (formerly Aventis Pasteur)), in collaboration with the Wistar Institute and the Children's Hospital of Philadelphia, is developing RotaTeq, an oral liquid pentavalent vaccine for the potential prevention of rotavirus infection-related disorders, such as infant diarrhea and malabsorption. Phase III trials had commenced by March 2001.
Insights
Sanofi Pasteur MSD is developing RotaTeq, an oral pentavalent vaccine to prevent rotavirus infections, including infant diarrhea. Phase III trials were underway by March 2001 for this important pediatric vaccine.
Area of Science:
- Vaccinology
- Pediatric infectious diseases
- Gastroenterology
Background:
- Rotavirus infection is a leading cause of severe diarrhea and malabsorption in infants globally.
- Effective prevention strategies are crucial to reduce infant morbidity and mortality.
Purpose of the Study:
- To develop and evaluate RotaTeq, an oral pentavalent vaccine for preventing rotavirus gastroenteritis in infants.
Main Methods:
- RotaTeq is an oral liquid pentavalent vaccine developed through a collaboration.
- Phase III clinical trials were initiated by March 2001 to assess efficacy and safety.
Main Results:
- The abstract does not contain specific results from the Phase III trials.
Conclusions:
- RotaTeq represents a promising development in the prevention of rotavirus-related infant disorders.
- Further data from ongoing trials are anticipated to confirm its effectiveness and safety profile.
